Despite setbacks and high risks, Eli Lilly & Co. continues to plunge ahead with its Alzheimer’s disease programs, announcing on April 17 that it has bought two tau imaging tracers and related technologies from Siemens Medical Solutions US.
The tracers are used with positron emission tomography to create images of tau tangles in the brain, and could be useful in monitoring treatment response and progression of Alzheimer’s disease, said Daniel Skovronsky, who founded Avid Radiopharmaecuticals Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?